SCHEMBL5896098

SCHEMBL5896098

O=C(O)/C(=C/c1ccc(-c2ccccc2)o1)NC(=O)c1ccc(O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.59
MAPK1 P28482 6/20 0.59
ALDH1A1 P00352 8/20 0.50
LMNA P02545 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MITF O75030 2/20 0.50
HTT P42858 1/20 0.50
GAA P10253 3/20 0.49
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
KDM4E B2RXH2 4/20 0.48
RAD52 P43351 1/20 0.48
POLB P06746 3/20 0.46
PKM P14618 2/20 0.46
HPGD P15428 3/20 0.45
NPC1 O15118 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TP53 P04637 1/20 0.45
RAB9A P51151 1/20 0.45
HCRTR1 O43613 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5896117 1.00 MAPT (0.59) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL5896112 1.00 MAPT (0.59) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL5897066 0.95 MAPT (0.59) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL5897053 0.95 MAPT (0.59) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL5897060 0.95 MAPT (0.59) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL5895812 0.92 MAPT (0.67) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL5895805 0.92 MAPT (0.67) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL5895791 0.92 MAPT (0.67) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL5896020 0.90 MAPT (0.65) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL5896030 0.90 MAPT (0.65) MAPTMAPK1ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 US disclosed
EP-1532128-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-05-25 EP disclosed
US-20040142980-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US disclosed
WO-2004002977-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142980-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 MAPT 3583/4885MAPK1 1713/4885ALDH1A1 832/4885
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI MAPT 3589/4885MAPK1 2559/4885ALDH1A1 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.